• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.12% Nasdaq Up0.71%

    Zogenix, Inc. (ZGNX)

    -NasdaqGM
    1.54 Down 0.11(6.67%) Apr 24, 4:00PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Zogenix, Inc.
    12400 High Bluff Drive
    Suite 650
    San Diego, CA 92130
    United States - Map
    Phone: 858-259-1165
    Fax: 858-259-1166
    Website: http://www.zogenix.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Drug Manufacturers - Major
    Full Time Employees:201

    Business Summary 

    Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. Its marketed product includes Zohydro ER, an extended-release formulation of hydrocodone for the treatment of severe chronic pain. The company also develops ZX008, a low-dose fenfluramine for the treatment of Dravet syndrome; and Relday, an injectable formulation of risperidone that is in Phase Ib clinical trial to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers with 13 years of age and older. It markets and sells its products to physicians, nurses, and other healthcare professionals. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in San Diego, California.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Zogenix, Inc.

    Corporate Governance 
    Zogenix, Inc.’s ISS Governance QuickScore as of Apr 1, 2015 is 10. The pillar scores are Audit: 5; Board: 10; Shareholder Rights: 8; Compensation: 10.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Mr. Roger L. Hawley , 62
    Chief Exec. Officer, Interim Chief Commercial Officer and Director
    645.00K0.00
    Dr. Stephen J. Farr Ph.D., 56
    Pres and Director
    530.00K0.00
    Ms. Ann D. Rhoads , 50
    Chief Financial Officer, Principal Accounting Officer, Exec. VP, Treasurer and Sec.
    472.00K0.00
    Dr. Bradley S. Galer M.D., 53
    Chief Medical Officer and Exec. VP
    71.00K0.00
    Mr. Jeff D. Durflinger , 54
    VP of Technical Operations & Product Supply
    N/AN/A
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders